ReviewJournal of mood and anxiety disorders2026
Bipolar disorder in oncology: Considerations for the psychiatrist.
Review in Journal of mood and anxiety disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bipolar disorder confers elevated cancer morbidity and mortality compared to the general population, yet bipolar disorder remains under-studied in oncology settings. Aims: This narrative review aimed to synthesize key considerations for psychiatrists and oncologists treating people with co-occurring bipolar disorder and cancer. Methods: A narrative review was performed to examine literature related to bipolar disorder in oncological care, focusing on outcomes, treatment-emergent mood symptoms, psychopharmacological interactions, and supportive interventions. Results: Bipolar disorder may adversely affect cancer care through reduced treatment engagement, diagnostic delays, and lower receipt of guideline-concordant oncologic therapy. Bipolar disorder is associated with increased risks of self-harm and suicide, as is receiving a cancer diagnosis. Cancer-related neurological conditions and treatments, including corticosteroids, antineoplastics, and interferon-alpha, may precipitate or worsen mood episodes. Mood stabilizers and antipsychotics carry clinically relevant risks including organ toxicity, electrolyte disturbances, cardiac effects, and immunosuppression. Nonpharmacologic strategies, particularly psychotherapy and maintenance of sleep stability, are essential care components. Discussion: Bipolar disorder has important implications for cancer treatment, while cancer and its therapies can destabilize mood and complicate psychiatric care. Early psychiatric care, close collaboration between oncology and psychiatry, careful medication selection and monitoring, attention to suicide risk and sleep, and psychosocial support are essential to improving care outcomes in this high-risk population. Future research addressing bipolar disorder as a distinct category within psycho-oncology rather than categorized under broader severe mental illness classifications will help further elucidate disorder-specific best practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.